CROISSY-BEAUBOURG, France & MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, ticker: ALTER, eligible for PEA-PME equity savings plans in France), a company specialising in in vitro diagnostics and theranostics, is pleased to announce the launch of a redeemable stock warrant (“BSAR”) free allocation plan for the benefit of its shareholders, at the rate of (1) warrant per share held with an exercise price of €4.
Theradiag’s Chief Executive Officer Michel Finance states: “We are pleased to be able to offer our shareholders the possibility of being awarded new shares if these stock warrants are exercised. By this mean, we wanted to thank all of our existing shareholders for their loyalty and unwavering support. In addition to improving the daily liquidity of our shares, this plan will enable Theradiag to benefit from the best possible conditions with a view to possible fund raising at a later date.”
Summary of the terms of the free allocation of BSAR redeemable stock warrants to all Theradiag shareholders:
This allocation follows the authorisation granted by shareholders at the Combined General Meeting of 27 April 2017 in the 12th resolution and the Board of Directors’ decision of 12 June 2017 to use this delegation of authority.
On 22 June 2017, each Theradiag shareholder will receive a free redeemable stock warrant for each share held. On the basis of the company’s share capital as of this date, a maximum of 8,654,944 warrants will be issued (before the elimination of treasury shares).
Holders of the warrants will be able to exercise them and obtain Theradiag shares as of the issue date of the warrants and for a period of 2 years (i.e. until 21 June 2019 inclusive). The exercise price of the warrants is set at €4 per share. On the basis of the exercise ratio, 7 warrants give the holder the right to subscribe to 1 new Theradiag share at a price of €4. The new shares subscribed on exercise of the warrants will be identical to existing shares as soon as they are issued.
The redeemable stock warrants – named Theradiag BSAR – will be listed and tradeable on Alternext under ISIN code FR0013260973 as of 20 June 2017.
The Company is not aware of the intentions of its major shareholders regarding the exercise of these warrants.
